CELU Celularity Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1752828 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.5%
TTM net income YoY34.7%
TTM EPS YoY43.2%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—
Margins
Gross margin55.1%
Operating margin-105.8%
Net margin-165.2%
FCF margin—
EBITDA margin-90.8%
Returns
ROE-6,367.2%
ROA-57.6%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets121.2%
Debt / equity—
Current ratio0.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.03x
Accruals ratio-55.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $26.55M | $54.22M |
| Cost of revenue | $20.07M | $14.99M |
| Gross profit | $6.48M | $39.23M |
| R&D expense | $15.03M | $17.39M |
| SG&A expense | $51.27M | $58.64M |
| Operating income | -$61.31M | -$38.36M |
| Pretax income | -$91.71M | -$57.89M |
| Income tax | $3,000 | — |
| Net income | -$91.72M | -$57.89M |
| EBITDA | -$54.01M | -$30.44M |
| EPS (basic) | -3.59 | -2.64 |
| EPS (diluted) | -3.59 | -2.64 |
| Weighted avg. shares (diluted) | 25.60M | 21.89M |
| Balance sheet | ||
| Cash & equivalents | $6.17M | $10.98M |
| Receivables | $4.65M | — |
| Inventory | $571,000 | $5.41M |
| Current assets | $12.32M | $20.56M |
| PP&E, net | $55.80M | $61.60M |
| Goodwill | $7.35M | $7.35M |
| Intangibles | $7.76M | $9.25M |
| Total assets | $107.33M | $132.68M |
| Current liabilities | $80.76M | $53.68M |
| Long-term debt | $33.81M | — |
| Total debt | $33.81M | — |
| Total liabilities | $145.39M | $123.84M |
| Shareholders' equity | -$38.06M | $8.84M |
| Net debt | $27.64M | — |
| Shares outstanding | 28.84M | 22.55M |
| Cash flow statement | ||
| Operating cash flow | -$13.25M | -$6.40M |
| Capital expenditure | — | $161,000 |
| Free cash flow | — | -$6.56M |
| Investing cash flow | — | $514,000 |
| Financing cash flow | $18.65M | $6.70M |
| Depreciation & amortization | $7.29M | $7.92M |
| Stock-based compensation | $10.64M | $11.57M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.